literature

HIV mutation literature information.

Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study.

PMID: 29892199 2018 Infection and drug resistance

Abstract: The most common emergent RAMs to NRTIs were M184V/I (42.3%) and K65R (28.2%), and those to nNRTIs were Y181C (42.3%), K103N (15.5%), G190A/E/Q (12.7%), V179D/E (12.7%), and V108I (9.9%).

Result: Of the 43 patients who received 2 NRTIs plus nevirapine, 19 (44.2%) had resistance to K65R and nNRTI with or without M184V/I.

Result: Of the emergent RAMs to NRTIs, M184V/I (42.3%) and

PMID: 29915897 2018 Drugs

Abstract: Resistance did not emerge to the STR components, with the exception being an emtricitabine resistance-associated mutation (RAM) [M184I/V] in one of seven recipients who experienced virological failure (although M184V was a minority variant at screening in this patient).

[Study on the relationship between HIV drug resistance and CD4(+)T cell counts among antiretroviral therapy patients with low viral load].

PMID: 29973007 2018 Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Abstract: The most frequent mutations were M184V/I (NNRTI), and the percentage was 26.1% (58 cases).

Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.

PMID: 29977795 2018 African journal of laboratory medicine

Discussion: K65R+ M184V/I would reduce susceptibility to tenofovir and didanosine from low-level (scores from 0 to 60) to high-level resistance (scores from 15 to 75).

Discussion: M184I was considered to be a transient mutation before being replaced by M184V.

Discussion: For instance, increased M184IV/I mutations would reduce susceptibility to lamivudine and emtricitabine (scores from 0 to 60, from susceptible to high-level of resistance).

Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.

PMID: 29977967 2018 Open forum infectious diseases

Introduction: Interestingly, the ANRS12286/MOBIDIP trial showed the superiority of DT with lamivudine plus bPI as compared with bPI monotherapy in a population of patients virologically suppressed on a second-line regimen of 2NRTI plus bPI, carrying the M184V mutation in many cases.

Introduction: Previous selection of M184V may impact clinical decisions to implement lamivudine-containing DT, yet a direct comparison of efficacy in patients harboring or not harboring the M184V mutation has not been performed.

Introduction: The M184V mutation is associated with high-level in vitro resistance to lamivudine but also with reduced viral replication capacity.

HIV-1 infection among crack cocaine users in a region far from the epicenter of the HIV epidemic in Brazil: Prevalence and molecular characteristics.

PMID: 30016324 2018 PloS one

Abstract: Isolates from two participants showed mutations associated with resistance to nucleoside reverse transcriptase inhibitors (NRTI) only (M41L, T125C, T125F, M184V), while an isolate from one patient who had received antiretroviral therapy (ART) since 2008 had a mutation associated with resistance to non-NRTI (G190S).

Antiretroviral resistance among HIV-1 patients on first-line therapy attending a comprehensive care clinic in Kenyatta National Hospital, Kenya: a retrospective analysis.

PMID: 30061964 2018 The Pan African medical journal

Abstract: Major NRTI mutations were detected in 11 patient samples, which included M184V (n = 6), M41L (n=3), D67N (n=2), K219Q (n=3) and T215F (n=2).

Result: Major NRTI mutations were detected in 11 patient samples, which included M184V (n=6), M41L (n=3), D67N (n=2), K219Q (n=3) and T215F (n=2).

Table: M184V

Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso.

PMID: 30079168 2018 Journal of public health in Africa

Abstract: M184V was the most frequent and was associated with highlevel resistance to 3TC, FTC, and ABC.

Result: Among the mutations identified, M184V was more predominant and was more frequent in mothers (27.78%) than in infants (22.22%).

Result: The drugs affected by these mutations were AZT (T215F/Y, D67N/E); 3TC (M184V, T215F/Y, D67N/E), FTC (M184V), ABC (M184V) and TDF (T215F/Y).

Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia.

PMID: 30137335 2018 The Journal of antimicrobial chemotherapy

Abstract: However, the detection of RAMs by UDS with a 1% cut-off was significantly higher than that of bulk sequencing for RT codons D67N (65.4% versus 52.3%), M184V (66.2% versus 52.3%), L210W (48.9% versus 36.4%) and T215Y (57.9% versus 42.1%) and PR codons M46I (46% versus 26%), I54L (12.4% versus 3.9%), V82A (44.5% versus 29.9%) and L90M (57.7% versus 42.5%).

The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.

PMID: 30174310 2018 Cell chemical biology

Abstract: Here, we report that EFdA and NRTIs with a 4'-ethynyl- or 4'-cyano-moiety exerted activity against HIV-1 with an M184V mutation and multiple NRTI-resistant HIV-1s, whereas NRTIs with other moieties (e.g., 4'-methyl) did not show this activity.

Abstract: Such interactions were maintained even in the presence of a broad resistance-endowing M184V substitution, thus potently inhibiting drug-resistant HIV-1 strains.

Result: 4'-Fluoromethyl and 4'-ethyl moiety of FMAdA-TP and EtAdA-TP had good interaction with wild-type HIV-1 RT (M184), but these interactions were reduced with M184V substitution (Figures 6C and E).

Browser Board

Co-occurred Entities

Filtrator